Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for CTXR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 66.61M
March 31, 2026 61.54M
December 31, 2025 79.96M
September 30, 2025 67.55M
June 30, 2025 65.06M
March 31, 2025 60.66M
December 31, 2024 65.41M
September 30, 2024 70.08M
June 30, 2024 85.68M
March 31, 2024 79.37M
December 31, 2023 84.73M
September 30, 2023 90.83M
June 30, 2023 97.70M
March 31, 2023 91.21M
December 31, 2022 100.43M
September 30, 2022 102.83M
June 30, 2022 109.74M
March 31, 2022 117.60M
December 31, 2021 123.96M
September 30, 2021 132.18M
June 30, 2021 136.68M
March 31, 2021 125.16M
December 31, 2020 25.20M
September 30, 2020 33.67M
June 30, 2020 28.74M
Date Value
March 31, 2020 22.44M
December 31, 2019 20.38M
September 30, 2019 24.38M
June 30, 2019 21.51M
March 31, 2019 20.87M
December 31, 2018 24.18M
September 30, 2018 27.87M
June 30, 2018 21.64M
March 31, 2018 23.50M
December 31, 2017 25.86M
September 30, 2017 21.95M
June 30, 2017 11.59M
March 31, 2017 13.99M
December 31, 2016 15.16M
September 30, 2016 16.77M
June 30, 2016 18.16M
March 31, 2016 20.43M
December 31, 2015 -1.590M
September 30, 2015 -0.6352M
June 30, 2015 -1.180M
March 31, 2015 -0.918M
December 31, 2014 -0.8235M
September 30, 2014
June 30, 2014 -0.0314M
March 31, 2014 -0.0251M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Citius Oncology, Inc. 40.38M
ANI Pharmaceuticals, Inc. 597.21M
Corcept Therapeutics, Inc. 705.78M
Veru, Inc. 28.38M
Johnson & Johnson 84.97B

Shareholders Equity (Quarterly) Related Metrics